The test, which uses melt curve analysis and runs on a fully integrated platform from Zeesan, may have a head start on MDR and XDR tests from other companies.
The company said it plans to use the proceeds to fund R&D, manufacture additional analyzers, and for general working capital, among other things.
It is the first FDA-approved test for the stem cell transplant use case and meets the WHO International Standard for comparable results.
The company currently offers target amplification assays for diagnostic use and clinical research that are based on a proprietary multiplex PCR technology.
The firm recently made strategic hires with commercialization experience in anticipation of bringing its handheld point-of-care device to market.
In Nature this week: genetic mechanism through which some cancers evade the immune system, and more.
The Wall Street Journal reports that Walgreens didn't fully vet Theranos before entering partnership.
Jeremy Berg is to be the next editor in chief of Science magazine.
Regeneron Pharmaceuticals is to be the new sponsor of the prestigious high school Science Talent Search competition, according to the New York Times.